Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes

Is statin use associated with better survival in different intrinsic subtypes of breast cancer (BC)?In this cohort study of 7389 patients with BC, postdiagnostic statin users had lowered BC-specific mortality (hazard ratio [HR], 0.68) and age-adjusted all-cause mortality (HR, 0.83) compared with nonusers. Statin use was associated with better BC-specific survival in hormone receptor–positive subtypes (luminal A-like, luminal B-like [HER2-negative], and luminal B-like [HER2-positive]).These findings suggest statin therapy may improve survival of patients with early hormone receptor–positive BC subtypes.

Corresponding Author: Santeri Palmi, MD, Department of Oncology, Tampere Cancer Center, Tampere University Hospital, Elämänaukio 2, 33520, Tampere, Finland (santeri.palmi@tuni.fi).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.